Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2020

Nov 16, 2020

SELL
$3.23 - $4.3 $6,783 - $9,030
-2,100 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$3.31 - $6.54 $6,951 - $13,734
2,100 New
2,100 $7,000

Others Institutions Holding ZYNE

About Zynerba Pharmaceuticals, Inc.


  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.